Glycoprotein IIb/IIIa antagonist and fibrinolytic agents: New therapeutic regimen for acute myocardial infarction

Journal of Invasive Cardiology

Volumn 12, Issue SUPPL. B, 2000, Pages

  Patel, Vasant B ^a   Moliterno, David J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT;

CLINICAL TRIAL; DRUG ANTAGONISM; DRUG COMBINATION; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; REVIEW;

CLINICAL TRIALS; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOLYTIC THERAPY;

EID: 0034145779     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. The GISSI Investigators. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet 1986;1:397-402.
2. The ISIS Investigators. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988;2:349-360.
3. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
4. The AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial. Lancet 1988;1:545-549.
5. Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital-initiated vs. hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. JAMA 1998;270:1211-1216.
6. Simoons ML, Serruys PW, van den Brand M, et al. Early thrombolysis in acute myocardial infarction: Limitation of infarct size and improved survival. J Am Coll Cardiol 1986;7:717-728.
7. Topol EJ, Califf RM, Vandormael M, et al. A randomized trial of late reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction-6 Study Group. Circulation 1992;85:2090-2099.
8. White HD, Norris RM, Brown MA, et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987;317-850-855.
9. Neuhaus KL, von Essen R, Tebbe U, et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: Results of the rt-PA-APSAC patency study (TAPS). J Am Coll Cardiol 1992;19:885-891.
10. Carney RJ, Murphy GA, Brandt TR, et al. Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarction. RAAMI Study Investigators. J Am Coll Cardiol 1992;20:17-23.
11. Smalling RW, Schumacher R, Morris D, et al. Improved infarct-related arterial patency after high dose, weight-adjusted, rapid infusion of tissue-type plasminogen activator in myocardial infarction: Results of a multicenter randomized trial of two dosage regimens. J Am Coll Cardiol 1990;15:915-921.
12. Neuhaus KL, Feuerer W, Jeep-Tebbe S, et al. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1989;14:1566-1569.
13. Miller JM, Ohman EM, Hasselblad V, et al. Can TIMI grade 3 flow at 60 minutes after thrombolysis substitute as a new angiographic standard? A meta-analytic approach. Circulation 1998;98:I-784.
14. Bode C, Smalling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996;94:891-898.
15. Cannon CP, Gibson CM, McCabe CH, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: Results of the TIMI 10B trial. Circulation 1998;98:2805-2814.
16. Ohman EM, Califf RM, Topol EJ, et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. Circulation 1990;82:781-791.
17. Lincoff AM, Topol EJ. Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation 1993;88:1361-1374.
18. Granger CB, Califf RM, Topol EJ. Thrombolytic therapy for acute myocardial infarction. A review. Drugs 1992;44:293-325.
19. Antman EM. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996;94:911-921.
20. Bleich SD, Nichols TC, Schumacher RR, et al. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990;66:1412-1417.
21. de Bono DP, Simoons ML, Tijssen J, et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: Results of a randomised double blind European Cooperative Study Group trial. Br Heart J 1992;67:122-128.
22. Merlini PA, Bauer KA, Oltrona L, et al. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. J Am Coll Cardiol 1995;25:203-209.
23. Golino P, Ashton JH, Glas-Greenwalt P, et al. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. Circulation 1988;77:678-684.
24. Gold HK, Coller BS, Yasuda T, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GP IIb/IIIa antibody in a canine preparation. Circulation 1998;77:670-677.
25. Holahan MA, Mellott MJ, Garsky VM, Shebuski RJ. Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis. Pharm 1991;42:340-348.
26. Mickelson JK, Simpson PJ, Cronin M, et al. Antiplatelet antibody [7E3 F(ab′)2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model. Circulation 1990;81:617-627.
27. Yasuda T, Gold HK, Fallon JT, et al. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest 1988;81:1284-1291.
28. Yasuda T, Gold HK, Leinbach RC, et al. Kistrin, a polypeptide platelet GP IIb/IIIa receptor antagonists, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation. Circulation 1991;83:1038-1047.
29. Yasuda T, Gold HK, Yaoita H, et al. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990;16:714-722.
30. Nicolini FA, Lee P, Rios G, et al. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation 1994;89:1802-1809.
31. Shebuski RJ, Stabilito IJ, Sitko GR, Polokoff MH. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bistatin in a canine model of coronary thrombosis. Circulation 1990;82:169-177.
32. Modi NB, Reynolds T, Baughman SA, et al. Pharmacokinetics and pharmacodynamics of TP-9201, a GP IIb/IIIa antagonist, administered in combination with recombinant tissue-type plasminogen activator, heparin, and aspirin in beagles. J Cardiovasc Pharm 1996;27:105-112.
33. Yasuda T, Gold HK, Kohmura C, et al. Intravenous and endobronchial administration of G4120, a cyclic Arg-Gly-Asp-containing platelet GP IIb/IIIa receptor-blocking pentapeptide, enhances and sustains coronary arterial thrombolysis with rt-PA in a canine preparation. Arterioscler Thromb 1998;13:738-747.
34. Jordan RE, Mascelli MA, Mace K, et al. Abciximab affords early and sustained reperfusion by reduced-dose reteplase in a primate model of severe arterial injury. Circulation 1998;98:I-526.
35. Kleiman NS, Ohman EM, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. J Am Coll Cardiol 1993;22:381-389.
36. Ohman EM, Kleiman NS, Gacioch G, et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation 1997;95:846-854.
37. Moliterno DJ, Harrington R, Califf RM, et al. Randomized, placebo-controlled study of lamifiban with thrombolytic therapy for the treatment of acute myocardial infarction: Rationale and design for the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) study. J Thrombosis Thrombol 1995;2:165-169.
38. Moliterno DJ, Topol EJ. Conjunctive use of platelet glycoprotein IIb/IIIa antagonists and thrombolytic therapy for acute myocardial infarction. Thrombosis Haemostasis 1997;78:214-219.
39. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 1999;99:2720-2732.
40. Dalen JE, Gore JM, Braunwald E, et al. Six- and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI). Am J Cardiol 1988;62:179-185.
41. Ohman EM. GUSTO IV/SPEED: GP IIb/IIIa blockade facilitates lysis. IIb/IIIa TODAY: Changing the practice of cardiovascular medicine. American Heart Association, 71st Annual Meeting, Dallas, Texas, 1998.
42. Van de Werf FJ. Combined fibrinolytic, glycoprotein IIb/IIIa receptor blockers and/or low molecular heparin. Optimal Reperfusion Therapy in the Next Millenium. European Society of Cardiology Meeting, Barcelona, Spain, 1999.
43. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Investigators. Lancet 1998;352:87-92.
44. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
45. The GUSTO IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. N Engl J Med 1996;335:775-782.
46. TIMI Research Group. Immediate vs. delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI-IIA results. JAMA 1988;260:2849-2858.
47. Simoons ML, Arnold AE, Betriu A, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: No additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988;1:197-203.
48. Topol EJ, Califf RM, George BS, et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987;317:581-588.
49. Rapold HJ, Grimaudo V, Declerck PJ, et al. Plasma levels of plasminogen activator inhibitor type 1, beta-thromboglobulin, and fibrinopeptide A before, during and after treatment of acute myocardial infarction with alteplase. Blood 1991;78:1490-1495.
50. Tripodi A, Bottasso B, Mannucci PM. Elevation of thrombin-antithrombin complexes during thrombolytic therapy in patients with myocardial infarction. Ric Clin Lab 1990;20:197-202.
51. Garcia-Avello A, Garcia-Frade LJ, Gandarias C, et al. High F1.2 fragment of prothrombin, thrombin-antithrombin III complex (TAT) and soluble fibrin plasma levels demonstrate hypercoagulability induced during loco-regional thrombolytic therapy with rt-PA. Thromb Res 1994;73:109-115.
52. Prager NA, Abendschein DR, McKenzie CR, Eisenberg PR. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation 1995;92:962-967.
53. Speidel CM, Thornton JD, Meng YY, et al. Procoagulant activity on injured arteries and associated thrombi is mediated primarily by the complex of tissue factor and factor VIIa. Coron Art Dis 1996;7:57-62.
54. Ewald GA, Eisenberg PR. Plasmin-mediated activation of contact system in response to pharmacological thrombolyis. Circulation 1995;91:28-36.
55. Shebuski RJ, Sitko GR, Claremon DA, et al. Inhibition of factor XIIIa in a canine model of coronary thrombosis: Effect on reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator. Blood 1990;75:1455-1459.
56. Nordt TK, Moser M, Kohler B, et al. Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction. Thromb Haem 1998;80:881-886.
57. Torr SR, Haskel EJ, Von Voigtlander PF, et al. Inhibition of cyclic flow variations and reocclusion after thrombolysis in dogs by a novel antagonist of platelet-activating factor. J Am Coll Cardiol 1991;18:1804-1810.
58. Saldeen TG, Saldeen P, Nichols WW, et al. Increased production of thromboxane A2 by coronary arteries after thrombolysis. Am Heart J 1993;125:277-284.
59. Fujikawa H, Kawasaki K, Sekiguchi H, et al. Endothelin-1 production in coronary circulation in a new canine model of coronary thrombosis. Cardiovasc Res 1996;32:604-612.